Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease
about
Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondiiAutophagy in neurodegenerative diseases: from mechanism to therapeutic approach2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative ActivityDiscovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activityNovel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expressionRestoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension.Mutagenesis Study Reveals the Rim of Catalytic Entry Site of HDAC4 and -5 as the Major Binding Surface of SMRT CorepressorFragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia.Evidence for a non-canonical role of HDAC5 in regulation of the cardiac Ncx1 and Bnp genes.LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.The potential of epigenetic therapies in neurodegenerative diseasesSelective class IIa HDAC inhibitors: myth or reality.Challenges of Huntington's disease and quest for therapeutic biomarkers.Guidelines for the successful generation of protein-ligand complex crystals.Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease.Insights into the Recruitment of Class IIa Histone Deacetylases (HDACs) to the SMRT/NCoR Transcriptional Repression Complex.Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling ApproachHistone deacetylase 6 structure and molecular basis of catalysis and inhibition.Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.Iodinated (Perfluoro)alkyl Quinoxalines by Atom Transfer Radical Addition Using ortho-Diisocyanoarenes as Radical Acceptors.Non-invasive diagnosis and treatment strategies for traumatic brain injury: an update.Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs.Therapy development in Huntington disease: From current strategies to emerging opportunities.Epigenetics and Metabolism in Health and DiseaseReconstitution of Mammalian Enzymatic Deacylation Reactions in Live Bacteria Using Native Acylated SubstratesIodierte (Perfluor)alkylchinoxaline über radikalische Atom-Transfer-Additionsreaktionen mit ortho -Diisocyanarenen als Radikalakzeptoren
P2860
Q22255525-8177538B-6BCE-4A5C-A9E8-73040F256829Q28084605-FD787F97-47CB-4106-9427-09F0491B052BQ28551721-2F29CBE5-B93E-463B-9B7A-40D6941FE15FQ33649465-441BE325-55BB-41DA-9F52-7B3826070B9BQ33789848-B4CC86AE-37F2-4FBA-AE12-6B7FB50B37F6Q34654695-EF4FD5D8-A30F-440E-8BB3-6EF3CB404633Q34945488-13DC9133-57EA-4ECC-AAAA-44F0C127020DQ35687733-F7B96D0E-E397-47CA-92A9-7E4C093EEDDFQ35824698-D0F20E4C-D9DA-40C6-AA30-1D72D4F9AE00Q36870458-A9988E38-7D75-4BE7-B803-2D5F71B86232Q37530359-81FD98B4-4B5C-40DD-8846-1DF0C55C0FAFQ38234971-990D35BE-85CE-4C69-BF49-E25D4657B464Q38246144-CD7D3D6F-E0B5-4789-BBA2-2183DE97783AQ38257697-E476A3DE-CD4F-4ACE-890B-8884A6602FCAQ38972442-E35B352B-D596-45BD-BEA9-55F72EF89C7AQ38973133-FA8D5A2A-56EB-4BF6-820B-A82A5ABF2D62Q40856825-FCBD711F-5BDF-4235-A36B-A80990984E1AQ41103388-B70F2BB5-4CE5-42E1-AC65-37A822CDB3C8Q41581397-B72884AD-66CF-490C-A1AE-81BE629200FDQ43083918-4EC05D92-3B45-4945-ACC3-5B1D7FEA1F65Q48118722-6D2DDE5F-D122-4FC7-BC47-2855E9036A32Q48142126-74470807-E49D-49FB-A12E-EAB8951024CBQ48212821-1880A94E-4249-45E5-9FF5-104F87B26776Q53716390-D6960586-B139-460E-BE76-F8F6FFC2952BQ57073692-1B1EBB66-9DFF-41E0-B027-671B64675865Q58744718-69727C3C-CD6A-43A7-8BA2-3E171C5AE9E0Q59222800-2149AE1C-0D7E-4B6F-AFA6-85032801F737
P2860
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Design, synthesis, and biologi ...... erapy for Huntington's disease
@ast
Design, synthesis, and biologi ...... erapy for Huntington's disease
@en
Design, synthesis, and biologi ...... erapy for Huntington's disease
@nl
type
label
Design, synthesis, and biologi ...... erapy for Huntington's disease
@ast
Design, synthesis, and biologi ...... erapy for Huntington's disease
@en
Design, synthesis, and biologi ...... erapy for Huntington's disease
@nl
prefLabel
Design, synthesis, and biologi ...... erapy for Huntington's disease
@ast
Design, synthesis, and biologi ...... erapy for Huntington's disease
@en
Design, synthesis, and biologi ...... erapy for Huntington's disease
@nl
P2093
P3181
P356
P1476
Design, synthesis, and biologi ...... erapy for Huntington's disease
@en
P2093
Alan F Haughan
Andrew J Stott
Catherine O'Connell
Celia Dominguez
Christine M Richardson
Christopher A Luckhurst
Dawn Yates
George McAllister
Grant Wishart
Hannah McNeil
P304
P3181
P356
10.1021/JM4011884
P407
P577
2013-12-05T00:00:00Z